ICTA

What ICTA does

ICTA is an independent, family-owned French Contract Research Organization (CRO) founded in 1984 in Fontaine-lès-Dijon by Dr. Michel Hantzperg and Dr. Aline Hantzperg. The company delivers full-service clinical development support — from feasibility and protocol design through regulatory affairs, project management, site monitoring, data management, biostatistics, medical writing, and vigilance — to three primary customer segments: Top 20 multinational pharmaceutical companies, biotechnology firms developing novel molecules, and medical device / medtech manufacturers requiring MDR (EU) 2017/745-compliant clinical evaluations. ICTA also runs dedicated practices in real-world evidence (RWE) studies, decentralized / hybrid trial design, and early access / compassionate use programs, supported by an in-house regulatory and digital health team.

The company's central technology asset is I-SIT (ICTA Secure Information Technology), a proprietary full-web integrated platform developed in-house since 2000 and validated against 21 CFR Part 11, GAMP 5, ISO 27001, ISO 9001, FDA, and GDPR requirements. I-SIT bundles modular components including e-CRF (electronic data capture), e-PRO (patient-reported outcomes), IWRS/RTSM (randomization and trial supply management), i-TMS (trial management), e-REPORT (sponsor reporting), i-COM (secure site communication), and a dedicated Early Access Program management module. All data is hosted on ICTA or OVH infrastructure in France with HDS (Hébergeur de Données de Santé) certification available.

ICTA operates a B2B, relationship-driven go-to-market with no public pricing; contracts are negotiated on a project basis against study complexity, therapeutic area, geographic scope, and duration. The company employs approximately 150 people (100 at Dijon HQ, ~50 distributed across France close to university hospitals) and reports annual revenue of approximately €15 million. Direct European subsidiaries — ICTA Iberia (Barcelona, via the integrated FreeCRA network), ICTA UK (Glasgow), and ICTA GmbH (Saarbrücken) — together with established site and investigator networks in France, Belgium, Italy, Germany, and Greece, support multi-country trial execution. Recent strategic emphasis has been on facility expansion (a 4,400 m² HQ extension is under construction), ESG and information-security credentialing (EcoVadis Silver Medal, ISO 27001), and entry into the S.O.L.V.E – AMR consortium targeting antimicrobial resistance drug development.

Name

ICTA

Legal name

ICTA PM

Website

https://icta.fr

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

251–500 employees

Short description

ICTA is a 40-year-old independent French CRO providing full-service clinical trial support — regulatory affairs, data management, biometrics, medical device evaluation, RWE, and early access programs — to Top 20 pharmaceutical, biotech, and medtech clients via its proprietary I-SIT platform.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Custom Computer Programming Services (541511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Electronic Data Capture (EDC) Platforms (HLACAOAA)

Keywords

• Contract research organization
• Clinical trial services
• Pharmaceutical CRO
• Medical device evaluation
• Real world evidence

Headquarters

HQ city

Fontaine-lès-dijon

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. CRO Services - Clinical Trial Management: ICTA operates as a full-service Contract Research Organization (CRO) providing comprehensive clinical research services. Revenue is generated through professional service fees for managing clinical trials on behalf of pharmaceutical, biotech, and medtech companies. Services span from study design through Clinical Study Report delivery, including regulatory affairs, project management, site support, monitoring, data management, biostatistics, medical writing, and vigilance. Annual revenue is approximately €15 million.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

ICTA is a full-service international Contract Research Organization (CRO) providing end-to-end clinical research services for pharmaceutical, biotech and medical device companies, from feasibility through Clinical Study Report delivery. Services span study design, regulatory affairs, project management, site support, risk-based monitoring, vigilance, data management, biostatistics and medical writing, supported by I-SIT®, ICTA's proprietary integrated e-clinical platform.

Product overview

ICTA is a full-service international CRO (Clinical Research Organization) founded in 1984, offering a comprehensive portfolio of clinical trial services. The company's core product is the I-SIT platform—a proprietary full-web collaborative system that integrates multiple modules including i-TMS (project management), e-REPORT (progress reporting), e-CRF (electronic data capture), e-PRO (patient-reported outcomes), IWRS/RTSM (randomization/supply management), i-COM (secure communication), and an Early Access Management Platform. ICTA provides end-to-end services spanning study design, regulatory affairs, project management, site support, risk-based monitoring, vigilance, data management, biostatistics, and medical writing. The company specializes in clinical development, real-world evidence studies, medical device evaluation, decentralized clinical studies, and early access programs across diverse therapeutic areas including oncology, rare diseases, and medical devices.

Differentiator

Problem solved

Functional benefit

Brands

• I-SIT: ICTA's proprietary full-web integrated IT platform for clinical trial management, eCRF, data management, and project coordination
• ICTA Iberia

Products and services

• Full-Service Clinical Development CRO Services
• Medical Device Clinical Evaluation Services
• Early Access Program (AAP) and Compassionate Use Program (CUP) Management Services
• Real World Evidence (RWE) Studies
• Decentralized and Hybrid Clinical Studies
• ICTA Iberia (Full-Service CRO in Spain and Portugal)
• FreeCRA Freelance CRA Sourcing Network

Quantifiable outcome

• 95% active sites achieved in international multi-country First-in-Human trial
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• S.O.L.V.E – AMR (Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance)coreStrategic or Co-development Partner · 10 October 2023Four recognized clinical research providers (BIOASTER, CYNBIOSE, ICTA, and PHARMALEX) have partnered to create S.O.L.V.E – AMR, a hub dedicated to combating antimicrobial resistance. The collaboration combines their expertise and competencies to offer integrated and innovative support throughout the development cycle of antimicrobial agents, from discovery to registration, including pre-clinical and clinical development. ICTA contributes clinical research expertise to accelerate anti-infectious product development.
• FreeCRA (now ICTA Iberia)coreStrategic or Co-development PartnerSince 2010, FreeCRA has been supporting sponsors, CROs, and clinical research stakeholders through a network of experienced professionals in Spain and Portugal. FreeCRA expertise covers startup services, feasibility, regulatory affairs, monitoring/site management, and study nursing. This collaboration has been formalized into ICTA Iberia, combining ICTA's full-service CRO expertise with FreeCRA's local knowledge and operational network in the Iberian Peninsula.
• AFCROs (Association Française des CROs)coreOthersICTA is an active member of AFCROs, the French Association of CROs. The company participates in AFCROs events including Clinical Research Day, Medical Device Day, and Real-World Healthcare Data Symposium, and hosts panel discussions on biotech and medtech topics.
• EUCROF (European CRO Federation)minorOthersMember of EUCROF, the European CRO Federation that promotes quality clinical research standards across Europe.
• BFCare (Bourgogne-Franche-Comté Competitiveness Cluster)minorOthersActive member of BFCare, the regional health competitiveness cluster in France, contributing to the development of the clinical research ecosystem and connecting with regional innovation stakeholders.
• Data Management Biomedical (DMB)minorOthersMember of DMB association, participating in annual conferences on eDC systems, regulations, and operational challenges in biomedical data management.
• Gynecological Investigator NetworkminorOthersClose collaboration with a gynecological network of investigators in France, enabling efficient patient recruitment and site management for gynecological oncology studies.
• European Clinical Research Sites (France, Belgium, Italy, Germany, Greece)coreOthersLong-standing European network of partners mandated for regulatory submissions and site management across multiple countries. Enables implementation of multi-country studies within expected timelines.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Parexel: Parexel is a global CRO providing Phase I–IV clinical research, regulatory, and market access services to biopharmaceutical clients worldwide. Comparable to ICTA as a full-service CRO with similar therapeutic area breadth but at significantly larger global scale.
• ICON plc: ICON is one of the largest global full-service CROs, providing Phase I–IV clinical trial management, biometrics, and laboratory services across all major therapeutic areas. Comparable to ICTA as a directly competing CRO offering the same end-to-end sponsor model, but at vastly greater scale and global reach.
• Syneos Health: Syneos Health is a fully integrated biopharmaceutical solutions organization offering clinical development and commercialization services globally. Directly comparable to ICTA's full-service CRO offering, though Syneos operates at much larger scale across North America, Europe, and Asia.
• Eurofins Scientific: Eurofins is a global leader in bioanalytical, central laboratory, and clinical trial support services with strong European presence. Comparable to ICTA on European reach and clinical trial services, though Eurofins is far larger and more diversified across testing and diagnostics.
• IQVIA: IQVIA is the world's largest CRO and life sciences technology provider, combining clinical trial services with real-world evidence, analytics, and technology platforms. Overlaps with ICTA's full-service CRO and RWE offerings, though IQVIA's scale, proprietary data assets, and US-centric footprint far exceed ICTA's.

Direct peers

• Celerion: Celerion is a mid-size CRO focused on early-phase clinical pharmacology, bioequivalence, and PK/PD studies. Comparable to ICTA on early-phase and specialized clinical trial services, though Celerion is more concentrated in early-stage clinical pharmacology.
• Premier Research: Premier Research is a mid-size global CRO specializing in complex therapeutic areas including oncology, rare disease, pediatrics, and medical devices. Closely comparable to ICTA on specialty expertise (especially oncology, rare disease, and MDR-focused medical device work) and mid-market positioning.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO providing full-service clinical development across complex therapeutic areas such as CNS, oncology, cardiometabolic, and rare diseases. Comparable to ICTA as a mid-sized, relationship-driven CRO competing for similar mid-market biopharma work.

Emerging players

• BioAgilytix Labs: BioAgilytix is a bioanalytical and specialized CRO supporting large-molecule, cell and gene therapy, and vaccine development. Overlaps with ICTA's ATMP and specialized therapeutic capabilities, though BioAgilytix is more concentrated on bioanalytical laboratory services.
• CROSSINGBIO: CROSSINGBIO is a European mid-size CRO offering clinical operations, biostatistics, data management, and regulatory affairs for pharma and biotech sponsors. Comparable to ICTA on European mid-market CRO positioning and full-service clinical research delivery, though smaller and earlier-stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICTA